sgp130 in Chronic Human Liver Disease

Alcoholic Liver Disease Clinical Trial

Official title:

Study of IL-6 Transsignaling in Chronic Human Liver Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00770198
• Other study ID #: AL-gp130
• Status: Completed
• Phase: N/A
• First received: October 8, 2008
• Last updated: October 8, 2008
• Start date: January 2005
• Est. completion date: October 2008

Study information

• Verified date: October 2008
• Source: Erasme University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Chronic liver disease are characterized by increased levels of plasma IL-6, but the bioactivity of this cytokine in this disease is not well known. IL-6 receptor complex is regulated by multiple receptors subunits: the soluble form of IL-6 Receptor enhance IL-6 signal by a process called trans-signaling on cells expressing few membrane IL-6 receptors. Soluble gp130 is the natural inhibitor of IL-6 trans-signaling. The aim of this study is to characterize circulating and liver levels of theses compounds of IL-6 receptor complex, to unravel the bioactivity of IL-6 in this disease.

Description:

Consecutive patients undergoing transjugular liver biopsies for alcoholic liver disease or hepatitis C virus infection will be included in the study to measure plasma cytokines levels, peripheral blood mononuclear cells cytokine release and liver IL-6R compounds mRNA levels.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: October 2008
• Est. primary completion date: January 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Alcohol excess intake and suspected liver disease

• Alcohol excess intake and clinical liver cirrhosis

• chronic hepatitis C virus infection and suspected liver disease

• chronic hepatitis C virus infection and clinical liver cirrhosis

Exclusion Criteria:

• other (superimposed) liver disease

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Alcoholic Liver Disease
• Chronic Hepatitis C Virus Infection
• Hepatitis C
• Hepatitis C, Chronic
• Hepatitis, Chronic
• Liver Diseases
• Liver Diseases, Alcoholic
• Virus Diseases

Locations

Country	Name	City	State
Belgium	Hopital Erasme - Dpt of Gastroenterology	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Erasme University Hospital

Country where clinical trial is conducted

Belgium,